Market Overview:
The global plasma derived drugs market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of chronic diseases, rising demand for plasma-derived drugs for the treatment of various diseases, and technological advancements in the field of plasma-derived drugs. Based on type, the global plasma derived drugs market is segmented into immunoglobulins, albumins, clotting factors, and others. Immunoglobulins are further sub-segmented into IgG antibodies and other immunoglobulins. Albumins are further sub-segmented into human albumin and animal albumin. Clotting factors are further sub-segmented into prothrombin complex concentrate (PCC), activated partial thromboplastin time (aPTT) assay reagents & kits, fibrinogen concentrate/fibrinogen replacement therapy products (FRC), erythrocyte sedimentation rate (ESR) assay reagents & kits and others). Others include coagulation factor concentrates such as von Willebrand factor (vWF) concentrate/von Willebrand disease treatment products and cryoprecipitate/cryosupernatant products.
Product Definition:
plasma derived drugs are medications that are made from human plasma. The plasma is collected from healthy donors and the proteins, antibodies, and other molecules that are needed to treat disease are isolated and purified. Plasma derived drugs have a number of important benefits over traditional medications. They are more pure than traditional medications, which means they can be less likely to cause side effects. They also tend to be more effective than traditional medications because they contain specific antibodies that target only the disease-causing proteins.
Immunoglobulins:
immunoglobulins, it's usage and growth factor in the plasma-derived drugs market? Immunoglobulins (IG) are a class of therapeutic proteins comprising three types: IgA, IgD, and IgE. They are majorly used for treatment of autoimmune diseases such as rheumatoid arthritis & Crohn’s disease. However, they also have applications in various other fields including transplantation rejection testing & tissue engineering.
Albumins:
Albumins are the major constituent of plasma and are mainly responsible for transporting substances between blood cells. They also have a vital role in maintaining the structural integrity of blood vessels. Albumins can be extracted from human milk or can be manufactured artificially by various processes such as micro-filtration, ultrafiltration, and coagulation.
Application Insights:
Based on application, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers and diagnostic centers. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of chronic diseases that require long-term treatment and higher number of surgeries every year. Plasma derived drugs are highly preferred by healthcare professionals for their use in various clinical applications due to its ability to treat several disorders at once without any harmful effects on the body.
The specialty clinic application segment is expected to witness lucrative growth over the forecast period owing to an increase in demand for low cost effective therapies that do not involve multiple visits or invasive procedures at a time when these treatments are required most often than not requiring only one or two doses per week depending upon disease state requiring less frequent dosing schedule which further reduces costs incurred by healthcare providers treating patients with special needs thus making it more affordable thereby contributing towards revenue generation among others (Hospitals).
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The region is expected to maintain its dominance over the forecast period as well owing to factors such as favorable reimbursement scenario, high healthcare expenditure, and presence of key manufacturers. Asia Pacific is estimated to be the fastest-growing regional market during the forecast period due to increasing healthcare spending by governments and private sectors along with rising awareness about plasma-derived drugs. Moreover, growing medical tourism industry will drive demand for plasma derived drugs in this region.
The European market also contributed significantly toward growth of this sector owing to establishment of strategic partnerships between major players.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. According to a study by the World Health Organization (WHO), chronic diseases are responsible for 63% of all deaths worldwide. This number is expected to increase to 73% by 2030. This presents a huge opportunity for plasma derived drugs market as these drugs are used extensively in the treatment of various chronic diseases such as cancer, diabetes, and rheumatoid arthritis, among others.
- Technological advancements: The plasma derived drugs market is witnessing rapid technological advancements, which is helping it expand at a fast pace. For instance, manufacturers are now using recombinant technology to produce high-quality plasma proteins and monoclonal antibodies for therapeutic use. Additionally, new methods such as chromatographic purification are being developed that can help reduce manufacturing costs while ensuring product quality and consistency. Such technological advancements are likely to fuel the growth of this market in the coming years..
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasma Derived Drugs Market Research Report
By Type
Immunoglobulins, Albumins, Clotting Factors, Others
By Application
Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others
By Companies
Grifols, S.A., Octapharma, Antares Pharma, CSL Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
175
Number of Tables & Figures
123
Customization Available
Yes, the report can be customized as per your need.
Global Plasma Derived Drugs Market Report Segments:
The global Plasma Derived Drugs market is segmented on the basis of:
Types
Immunoglobulins, Albumins, Clotting Factors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Grifols, S.A.
- Octapharma
- Antares Pharma
- CSL Limited
Highlights of The Plasma Derived Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunoglobulins
- Albumins
- Clotting Factors
- Others
- By Application:
- Hospitals
- Speciality Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasma Derived Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasma derived drugs are medications that are created by extracting the blood plasma from a patient. This process separates the proteins, cells, and other substances from the blood plasma. The extracted substances can then be used to create medications.
Some of the major companies in the plasma derived drugs market are Grifols, S.A., Octapharma, Antares Pharma, CSL Limited.
The plasma derived drugs market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasma Derived Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Plasma Derived Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Plasma Derived Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Plasma Derived Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Plasma Derived Drugs Market Size & Forecast, 2020-2028 4.5.1 Plasma Derived Drugs Market Size and Y-o-Y Growth 4.5.2 Plasma Derived Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Immunoglobulins
5.2.2 Albumins
5.2.3 Clotting Factors
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Speciality Clinics
6.2.3 Ambulatory Surgical Centers
6.2.4 Diagnostic Centers
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasma Derived Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasma Derived Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Immunoglobulins
9.6.2 Albumins
9.6.3 Clotting Factors
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Speciality Clinics
9.10.3 Ambulatory Surgical Centers
9.10.4 Diagnostic Centers
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Immunoglobulins
10.6.2 Albumins
10.6.3 Clotting Factors
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Speciality Clinics
10.10.3 Ambulatory Surgical Centers
10.10.4 Diagnostic Centers
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Immunoglobulins
11.6.2 Albumins
11.6.3 Clotting Factors
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Speciality Clinics
11.10.3 Ambulatory Surgical Centers
11.10.4 Diagnostic Centers
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Immunoglobulins
12.6.2 Albumins
12.6.3 Clotting Factors
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Speciality Clinics
12.10.3 Ambulatory Surgical Centers
12.10.4 Diagnostic Centers
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Immunoglobulins
13.6.2 Albumins
13.6.3 Clotting Factors
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Speciality Clinics
13.10.3 Ambulatory Surgical Centers
13.10.4 Diagnostic Centers
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasma Derived Drugs Market: Competitive Dashboard
14.2 Global Plasma Derived Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Grifols, S.A.
14.3.2 Octapharma
14.3.3 Antares Pharma
14.3.4 CSL Limited